title: C4d-positive renal allograft rejection biopsies in cyclosporine-treated patients: single-center incidence and outcome.
abstract: T cell-mediated acute rejection (ATCMR) in renal transplant patients can have an antibody-mediated component. The aim of this study was to evaluate the incidence of renal biopsies showing ATCMR with C4d immunoreactivity and the correlation between C4d-positive ATCMRs and graft outcomes. We studied 216 renal transplant patients receiving cyclosporine-based immunosuppression (mean follow-up = 203.5 +/- 42.5 months). Of these, 79 experienced biopsy-proven ATCMR (group 1), whereas 137 did not show clinical or laboratory evidence of ATCMR (group 2). Mean serum creatinine levels were evaluated at 6 months, as well as 2 and 5 years after transplantation. The number of graft losses due to interstitial fibrosis and tubular atrophy (IF/TA) was greater in group 1 than in group 2 (P < .001 and P < .02, respectively), while graft survival was lower (P < .03). Staining with anti-C4d antibody was performed in 61/77 type I ATCMR biopsies: seven cases showed diffuse C4d positivity with CD68(+) monocytes in peritubular capillaries observed in all cases. Three cases showed focal C4d positivity. Two ATCMRs were steroid, resistant. Graft loss due to IF/TA occurred in 4/7 patients (57.1%) who had previously experienced ATCMRs with diffuse C4d positivity; whereas it occurred in 5/51 patients (9.8%) with previous C4d negative ATCMRs (P < .001). Patients with focal C4d positivity did not undergo graft loss due to IF/TA. In conclusion, at our center the diffuse C4d positivity that occurred in 11.4% of type I ATCMRs was associated with a poor prognosis.
authors.affiliation: Department of Diagnostic Medical Sciences, Section of Special Pathology, Unit of Kidney and Pancreas Transplantation, University of Padua, Medical School, Padua, Italy. marialuisa.valente@unipd.it
authors.forename: M
authors.initials: M
authors.lastname: Valente
authors.forename: L
authors.initials: L
authors.lastname: Furian
authors.forename: F
authors.initials: F
authors.lastname: Marchini
authors.forename: S
authors.initials: S
authors.lastname: Marino
authors.forename: M
authors.initials: M
authors.lastname: Cardillo
authors.forename: P
authors.initials: P
authors.lastname: Rigotti
authors.forename: F B
authors.initials: FB
authors.lastname: Aiello
mesh_terms: D000328:Adult; D001706:Biopsy; D015935:Complement C4b / Q000032:analysis*; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology / Q000473:pathology*; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis*; D012189:Retrospective Studies; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D010446:Peptide Fragments; D015935:Complement C4b; C032261:complement C4d; D003404:Creatinine